Recent studies indicate, however, that the molecular biochemistry may be more complex. Two general approaches have been taken with the drug-based approach. The first is the blockade of the androgen precursor enzyme 5 alpha reductase (5AR).

Although the functional significance of the differential subcellular localization of type 1 and 2 isoenzymes in the hair follicle is currently unknown, the present data suggest that both 5AR isoforms may contribute to phenotype in an additive or synergistic manner. Aside from surgical restoration and/or hair replacement wig systems, the two most com ways to treat pattern hair loss, also known as androgenetic alopecia (AGA) are medical drug-based therapy and non-drug botanical therapy. Today, we shall examine the underlying basis for therapeutic hair loss treatment options commercially available in the marketplace. Two isoforms of 5AR have been identified, each distinct from the other by pH and tissue localization. The oral 5AR blocking drugs presently approved by the FDA for treating AGA are finasteride, a selective.

Type 2 5AR has long been more strongly linked to pattern hair loss while type 1 5AR was thought to be less important.